PCSK9 has been reported as a therapeutic target for patients with dyslipidemia or hypercholesterolemia, and overexpression of PCSK9 is associated with oncogenesis and enhances the malignant phenotypes of CRC with APC/KRAS mutations. This evidence concerns the gene PCSK9 and metabolic syndrome.